comprehensive -WSS

comprehensive

author：focus 2025-09-14 11:46:48 - browse：1354

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： HPV vaccine, cervical cancer study delivers historic results

focus

WSS

Adam's Take: Intra

This gene therapy has record $4.25 million price. It's saved children.

This gene therapy has record $4.25 million price. It's saved children.

Erich Jarvis studies song birds to learn about human stuttering

Printout prescription drug information shouldn’t go digital

Adam's Take: Intra

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Affirmative action in medical school literally saved lives

CVS is on a mission to consolidate health care. Will it work?

Wildfire smoke exposes gaps in outdoor worker protections

U.K. officials, researchers try to ease path for bespoke genetic treatments

Supreme Court strikes down use of affirmative action

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

As demand for Covid shots wanes, Moderna seeks its next success

To bolster infectious disease surveillance, genomics powerhouses team up

leisure time

Inaction leaves children at risk from dangerous chemotherapy drug

Future doctors need a strong humanities education

'Patient friction coefficient' can gauge a clinical trial's patient burden

Pregnancy ages women, but effects reverse after delivery

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

A pediatrician calls for Congress to pass the child tax credit deal

explore

focus

hotspot

entertainment